Maria Carmen Ochoa

NK‐cell reactivity against cancer is conceivably suppressed in the tumor microenvironment by the interaction of the inhibitory receptor NKG2A with the non‐classical MHC‐I molecules HLA‐E in humans or Qa‐1 b in mice. We found that intratumoral delivery of NK cells attains significant therapeutic effects only if co‐injected with anti‐NKG2A and anti‐Qa‐1 b blocking monoclonal antibodies against solid mouse tumor models. Such therapeutic activity was contingent on endogenous CD8 T cells and type‐1 conventional dendritic cells (cDC1). Moreover, the anti‐tumor effects were enhanced upon combination with systemic anti‐PD‐1 mAb treatment and achieved partial abscopal efficacy against distant non‐injected tumors. In xenografted mice bearing HLA‐E‐expressing human cancer cells, intratumoral co‐injection of activated allogeneic human NK cells and clinical‐grade anti‐NKG2A mAb (monalizumab) synergistically achieved therapeutic effects. In conclusion, these studies provide evidence for the clinical potential of intratumoral NK cell‐based immunotherapies that exert their anti‐tumor efficacy as a result of eliciting endogenous T‐cell responses.